Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells
Status:
Unknown status
Trial end date:
2019-11-27
Target enrollment:
Participant gender:
Summary
NK cells can persist and expand in vivo following adoptive transfer and may have a role in
the treatment of late stage malignancies. NK also express an activating Fc receptor that
mediates antibody-dependent cellular cytotoxicity (ADCC) and production of immune modulatory
cytokines in response to antibody-coated targets. Nimotuzumab, an monoclonal antibody against
EGFR (epidermal growth factor receptor), may enhance the ADCC effect of NK cell. This study
will evaluate the safety of combination of nimotuzumab and NK Cell in treating advanced
cancer patients. Blood samples will also be collected for research purposes.